A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 17,100 shares of RVNC stock, worth $43,947. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,100
Previous 3,100 451.61%
Holding current value
$43,947
Previous $27,000 211.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $79,515 - $159,201
17,100 New
17,100 $84,000
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $7.88 Million - $17.2 Million
686,735 Added 101.52%
1,363,168 $15.6 Million
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $16.7 Million - $25.4 Million
676,433 New
676,433 $17.1 Million
Q2 2022

Aug 15, 2022

SELL
$11.52 - $20.4 $2.09 Million - $3.7 Million
-181,393 Reduced 23.05%
605,574 $8.37 Million
Q1 2022

May 16, 2022

SELL
$12.36 - $20.31 $1.17 Million - $1.92 Million
-94,515 Reduced 10.72%
786,967 $15.3 Million
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $1.58 Million - $3.53 Million
126,682 Added 16.78%
881,482 $14.4 Million
Q3 2021

Nov 15, 2021

BUY
$25.78 - $33.21 $19.5 Million - $25.1 Million
754,800 New
754,800 $21 Million
Q2 2021

Aug 16, 2021

SELL
$26.8 - $31.84 $7.19 Million - $8.55 Million
-268,400 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$24.03 - $29.97 $6.45 Million - $8.04 Million
268,400 New
268,400 $7.5 Million
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $3.3 Million - $7.38 Million
-265,199 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $548,533 - $947,936
47,044 Added 21.56%
265,199 $4.3 Million
Q3 2019

Nov 15, 2019

BUY
$10.22 - $14.5 $1.05 Million - $1.49 Million
102,455 Added 88.55%
218,155 $2.84 Million
Q2 2019

Aug 14, 2019

BUY
$10.67 - $15.49 $1.23 Million - $1.79 Million
115,700 New
115,700 $1.5 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.